(Source: Xencor Inc) MONROVIA, Calif., June 14, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company will host an Analyst Day on Tuesday, June 28, 2016, from 8:30 a.m. - 11:30 a.m. ET in New York City. During the Analyst Day, members of Xencor's management team will provide updates on the...
↧